Press Kit
Boilerplate
Owkin is an agentic AI company pioneering Biological Artificial Superintelligence to solve problems in biology where human researchers alone have failed.
Owkin builds K Pro - an AI scientist for pharmaceutical research and strategic decision-making. K Pro orchestrates a suite of AI skills and tools to decode complex biology, accelerate research, and dramatically increase productivity.
K Pro is built on Owkin’s unrivalled multimodal patient data network, state-of-the-art AI for biology and a decade of experience working with pharmaceutical partners.
Media contact
For international media requests, please contact alistair.jennings@owkin.com
For French media requests, please contact malika.labou-ext@owkin.com
About our founder
Thomas leads Owkin as CEO. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and former member of Ari Melnick’s lab at the Weill Cornell Medical College.
He ensures that patient health is prioritized when developing breakthrough medical technologies, bringing a patient-centric approach to each Owkin project.
Owkin FAQs
Owkin is a French-American AI company with teams across Europe and the United States.
Owkin was co-founded by Thomas Clozel, MD, a former assistant professor in clinical hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016.
Owkin was founded with the belief that the future of health is in technologies that are able to unlock insights from the vast amount of patient data in hospitals and research centers in a privacy-preserving and secure way.
Owkin is differentiated by a focus on building Biological Artificial Superintelligence (BASI) to improve our fundamental understanding of disease biology.
We believe this will be best achieved through analysis of multimodal patient data and its use in training cutting-edge AI, grounded in biology.
We have built an unrivalled network of leading researchers, academic centres and hospitals in order to access, understand and properly characterise our patient data.
Our AI scientist - K Pro - can analyze multimodal data, identify novel targets and biomarkers, report on the business environment for a given asset and much more.
We believe that all AI looking to understand disease biology must be grounded in reality - hence we test our AI models’ predictions with patients in the real world, through our INVOKE clinical trial and through our diagnostic partner Waiv.
By understanding complex biology through AI, we speed up pharmaceutical R&D, identify new treatments, and de-risk and accelerate clinical trials.
Owkin's founding mission is to improve medical research in a way that protects data privacy and security.
Owkin is ISO27001:2022 and NIS2 certified and is committed to the protection of customer information in accordance with global security requirements, as well as with applicable legal and regulatory frameworks. Owkin is also CSA - Star 1 Registry, which shows our commitment to Cloud Security.
Owkin relies on a set of organizational and technical measures to ensure security objectives are achieved. Internal and external audits are performed regularly and with every major change to Owkin’s Information Systems. A Security Risk Assessment is performed on the whole organisation and regularly reviewed to keep up to date regarding security and privacy threats.
Owkin has also received ISO13485:2016 certification for the design, development, manufacturing, and distribution of its AI IVD diagnostic solutions. This certification highlights Owkin’s ability to deliver clinically robust solutions for unmet medical needs, developed with the highest quality and safety standards.
Learn more from Owkin’s Trust Centre
Owkin has raised $304.1m USD from investors such as Bpifrance Large Ventures, GV, NJF Capital, Cathay Innovation, F-Prime, Otium Capital, Eight Roads Ventures, Plug and Play, Mubadala and MACSF (French Pension Fund for Clinicians), as well as corporate institutional partners such as Sanofi and Bristol-Myers Squibb.
Funding Rounds
- Seed Round: $2.1M
- Series A: $72M
- Series B: $230M